📄 Extracted Text (600 words)
To:
From: James Meiskin
Sent Wed 5/21/2014 10:05:40 PM
Subject Re: Confidential
Confirmed. Thank you
Sent from my iPhone
On May 21, 2014, at 5:51 PM wrote:
Jeffrey's home, 9 East 71st Street between 5th and Madison... 5pm would be
great.
On May 21, 2014, at 5:14 PM, James Meiskin
wrote:
That will work. Do you have a time and location in mind? Thank you,
James
Sent from my iPhone
On May 21, 2014, at 10:25 AM, wrote:
Great. Would Sunday June 1st work?
Sent from my iPhone
On May 21, 2014, at 9:47 AM, James Meiskin
wrote:
Of course. Please get me dates that work for
Jeffrey, and I will have David fly in from CA
to meet him withi r,sure.
Hope your well
Best, James
Sent from my iPhone
On May 21, 2014, at 9:41 AM, M la•
wrote:
HI James....below is Jeffrey's
response:
EFTA_R1_00718225
EFTA02104914
im not in ny until June but happy
to see you both after
Might it be possible to schedule something the beginning of
June?
On May 21, 2014, at 9:23 AM, "James Meiskin"
wrote:
Jeffrey, David
Carter (Company
information is
attached), is in NY
today and
tomorrow morning,
and I felt that it
could be beneficial
and timely for you
to further learn
about this
opportunity if there
was interest on
your end. Please
take a moment to
review the
attached material.
and let me know if
you would like to
meet while David is
in NYC. Best
Regards, James
Dear
James,
Like I
have
said in
an
earlier
email. I
am
looking
EFTA_R1_00718226
EFTA02104915
for an
"investi
ng
partner
" to
match
(50%/S
0%) the
money
Russian
Ventur
e
Capital
plans to
invest
in USA
based
Biotech
nology.
They
will
provide
half of
the
capital
to
develop
a
variety
of
technol
ogies
that are
of
interest
to their
country
. For
their
investm
ent
they
get
comme
rcializat
ion
rights
to the
EFTA_R1_00718227
EFTA02104916
technol
ogies
they
finance
for
Russia
and the
CIS.
For us,
on the
USA
side,
this is a
major
source
of
capital
to start
a series
of
compan
ies that
have
great
potenti
al as
therape
utic
technol
ogies,
and we
get
comme
rcializat
ion
rights
for the
USA,
and
rest of
the
world
market
s.
Basicall
y, we
get the
rights
EFTA_R1_00718228
EFTA02104917
that are
valuabl
e to us
at "half
price".
Over
the
next
several
years
our
plan is
to
identify
seven/e
ight
technol
ogies
that are
worthy
of
develop
ment.
RVC has
already
agreed
to
finance
the first
(MAJI)
and is
looking
at the
next
two—P
redictio
n
Bioscie
nces,
and
Ovation
Bio. I
have
several
more
currentl
y in
EFTA_R1_00718229
EFTA02104918
diligenc
e. (The
original
Investo
r
Present
ation
made
in
Mosco
w is
attache
d)
So, I am
looking
for a
source
of
capital
that
thinks
this is
an
interest
ing
investm
ent
theme,
and is
willing
to
conside
r the
idea as
someth
ing they
might
want to
implem
ent.
My
belief is
that
there is
more
money
in NYC,
EFTA_R1_00718230
EFTA02104919
seeking
an
investm
ent
home,
then
there
are
"quality
investm
ent
ideas".
I could
be
wrong,
but I
have to
believe
that
people
running
a lot of
capital
in New
York
would
want to
hear
new,
creative
,and
GOOD
new
investm
ent
ideas. I
think
this
idea is
the
kind of
idea
that is
worth a
look,
and
worth
serious
EFTA_R1_00718231
EFTA02104920
conside
ration.
I think
we are
talking
$150M
over a
five
year
horizon
Best,
David
David
W.
Carter
Preside
nt—Da
Cart
Capital
LIC
<DaCart
Presentation.pptx
EFTA_R1_00718232
EFTA02104921
ℹ️ Document Details
SHA-256
4d04882ed54fbf25e7cecdea4877d4315f14289de82d761be2a79615702635b4
Bates Number
EFTA02104914
Dataset
DataSet-10
Document Type
document
Pages
8
Comments 0